Skip to main content
. Author manuscript; available in PMC: 2024 Jun 7.
Published in final edited form as: Explor Med. 2024 Apr 12;5(2):193–214. doi: 10.37349/emed.2024.00216

Table 6.

The association between circulating CD34+CD133+ cells and the risk of AD in the context of genetic background

rs4144611 (KIRREL3) rs580382 (KIRREL3) rs61619102 (EXOC6B)
Genotype CD34+CD133+
cutoffs
HR
(95% CI)
P value Genotype CD34+CD133+
cutoffs
HR
(95% CI)
P value Genotype CD34+CD133+
cutoffs
HR
(95% CI)
P value
TT 25% 0.18 (0.07–0.46) 3.3 × 10−4* CC 25% 0.21 (0.09–0.47) 1.7 × 10−4* CC 25% 0.48 (0.26–0.88) 0.02*
50% 0.11 (0.03–0.42) 0.001* 50% 0.16 (0.05–0.47) 9.6 × 10−4* 50% 0.38 (0.19–0.74) 0.005*
75% N/A (zero AD) 0.006a* 75% N/A (zero AD) 0.002a* 75% 0.25 (0.08–0.81) 0.02*
GG + TG 25% 1.02 (0.46–2.25) 0.96 TT + CT 25% 1.80 (0.68–4.82) 0.24 GG + GC 25% 2.22 (0.39–12.64) 0.37
50% 1.54 (0.76–3.15) 0.23 50% 2.44 (1.07–5.56) 0.03* 50% 12.38 (2.00–76.65) 0.007*
75% 1.39 (0.64–3.05) 0.41 75% 1.80 (0.80–4.07) 0.16 75% 5.68 (1.65–19.61) 0.006*

Participants were first stratified into KIRREL3 rs4144611 TT vs. GG + TG; rs580382 CC vs. TT + CT as well as in EXOC6B rs61619102 CC vs. GG + GC genotype groups. Using Cox proportional hazards regression model, AD incidence was associated with (CD34+CD133+ cutoffs: 25%, 50%, and 75%) after adjusting for age, sex, years of education, APOE ε4, and PCs for each genotype group. a When CD34+CD133+ is higher than the 75% percentile, there are no AD cases among these genotypes, KIRREL3 rs4144611 TT, KIRREL3 rs580382 CC, and EXOC6B; * P value significant < 0.05